Unitaid
- Company typePrivate
- Founded2006
- HeadquartersGeneva, Switzerland
- Headcount101–250
- GTM typeB2B
- OfferingServices
Unitaid firmographics
Firmographics- Name
- Unitaid
- Legal name
- Unitaid
- Website
- https://unitaid.org
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Unitaid industry classification
Industry- Product category
- Global Health Financing and Market Shaping
- NAICS
- Voluntary Health Organizations (813212), Grantmaking and Giving Services (81321)
- SIC
- Services-Social Services (8300)
- akta.pro primary industry
- Global Health Financing Mechanisms (HLAJAKAC)
- akta.pro secondary industries
- Multilateral Global Health Agencies (UN/IFIs) (HLAJAKAA), Global Health Supply Chain & Procurement Organizations (HLAJAKAL), Disease-Specific Global Programs (HIV/TB/Malaria/NTDs) (HLAJAKAF), Global Health Financing Mechanisms & Pooled Funds (HLAJAOAC), Health Supply Chain, Procurement & Access to Medicines (BPADAIAI)
Keywords
Where Unitaid is headquartered
LocationHeadquarters
- HQ city
- Geneva
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Unitaid business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure, Technology or R&D
Revenue model
- Grants and Donations: Unitaid receives financial investments from governments (Brazil, Canada, Chile, France, Japan, Norway, Portugal, Republic of Korea, Spain, United Kingdom), the European Union, Gates Foundation, Wellcome, and WHO Foundation. Founded in 2006 by Brazil, Chile, France, Norway and the United Kingdom.
- Innovative Financing: Uses innovative financing solutions like volume guarantees to lower prices for health products and help get them to market. Building on legacy of successful innovative health financing including air levy mechanisms.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Annual | Lenacapavir generic version - approximately £30 per person per year |
| Unit Pricing | Annual | Lenacapavir generic version - $40 per person annually |
| Unit Pricing | Pay-as-you-go | AirRay 20 X-ray system - discounted pricing for 138 LMICs |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels7 records
Unitaid product offering
Product offeringCore offering
Unitaid finances and accelerates the development, introduction, and scale-up of innovative health products for HIV, tuberculosis, malaria, women's and children's health, and pandemic preparedness in low- and middle-income countries. It does this primarily through grants to implementing partners and market-shaping agreements (volume guarantees, ceiling prices, and technology partnerships) that drive down product costs and accelerate access for the people who need them most.
Product overview
Unitaid does not offer a single unified product but rather a portfolio of health product investments and initiatives across multiple disease areas. The organization works to accelerate access to innovative health products including: HIV prevention tools (lenacapavir twice-yearly injection), AI-powered diagnostic solutions (miLab CER for cervical cancer, AirRay 20 for TB screening), advanced HIV disease diagnostics (VITA CD4 Test), and novel testing approaches (pooled TB testing). Unitaid also supports regional manufacturing initiatives (MADE, MedSuRe Africa) to strengthen Africa's health product supply chains.
Differentiator
Problem solved
Functional benefit
Products and services
- MADE Program (Market Access and Diagnostic Equity) Unitaid-funded program that supports African manufacturers in developing and scaling diagnostic test production for regional and global markets, addressing the 70% of pharmaceuticals consumed in Africa that are imported.
- MedSuRe Africa Program Unitaid-funded program led by US Pharmacopeia (USP) that boosts regional production of essential medicines (including HIV, malaria, and postpartum hemorrhage treatments) and related quality testing infrastructure in Africa.
- Antimalarial Drug Resistance Initiative A US$26.5 million Unitaid-funded initiative led with Jhpiego to curb rising antimalarial drug resistance in Africa.
- Cervical Cancer Elimination Call for Proposals (Secondary Prevention) Unitaid funding call worth up to US$50 million for projects accelerating cervical cancer elimination through secondary prevention (screening and pre-cancer treatment) in low- and middle-income countries.
- Climate-Proof Health Products Funding Opportunity A US$10 million Unitaid funding opportunity to generate evidence on how extreme heat and humidity affect the safety, quality and effectiveness of essential medicines and health products in LMICs.
- Pregnant Women's Care Expansion Initiative A US$52 million Unitaid investment to expand lifesaving care for pregnant women in Africa.
Quantifiable outcome
- 390 million people benefit annually from Unitaid-supported health products
- +5 more outcomes
Companies that use Unitaid
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles4 records
Unitaid technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature3 records
Unitaid partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core, supporting and flagship.
- Elton John AIDS FoundationcoreUnitaid and Elton John AIDS Foundation advocating for urgent scale-up of lenacapavir for adolescent girls and young women in sub-Saharan Africa. Organizations secured ceiling price of approximately £30 per person per year for quality-assured generic versions.
- Clinton Health Access Initiative (CHAI)coreUnitaid, CHAI, and Wits RHI coordinated with Dr. Reddy's Laboratories to supply generic lenacapavir at $40 per person annually for 120 LMICs. Proof that early market-shaping can make affordability keep pace with innovation.
- Wits RHIcoreWits RHI collaborated with Unitaid and CHAI to coordinate lenacapavir generic pricing agreement with Dr. Reddy's Laboratories for 120 low- and middle-income countries.
- FiocruzcoreSouth Africa negotiating voluntary license agreement with Gilead Sciences with support from Unitaid and US Pharmacopeia. Lenacapavir use kicked off in South Africa and Brazil through Unitaid partnership with Wits RHI and Fiocruz.
- FINDcoreUnitaid invested US$44 million since 2022 to advance TB diagnostics through partnerships with LSTM and FIND. Multi-country trial demonstrated pooled testing reducing TB testing costs by up to 65%.
- Liverpool School of Tropical Medicine (LSTM)coreUnitaid partnership with LSTM supporting TB diagnostics advancement as part of US$44 million investment since 2022.
- Noul Co. LtdsupportingNoul debuted AI-powered cervical cancer diagnostic solution miLab CER at CES 2026. Unitaid recommended miLab CER for use in 2024 alongside solutions from Roche and Hologic.
- Accesso BiotechsupportingSupport from Gates Foundation, Unitaid, and CHAI to expand manufacturing and global access to VITA CD4 test for managing advanced HIV disease. Initiative aims to accelerate regulatory approval and scale production.
- Dr. Reddy's LaboratoriescoreIndian pharmaceutical company plan to produce generic versions of lenacapavir for $40 a year starting in 2027. Supported by Unitaid, Clinton Health Access Initiative, and Wits RHI to expand competitive generics ecosystem for the drug.
- Hetero LabscoreGates Foundation partnership with Indian manufacturer Hetero Labs to produce low-cost generic version of lenacapavir at roughly $40 per patient per year, pending regulatory approval expected as early as 2027. Part of broader effort to accelerate affordable access to lenacapavir in LMICs.
- PATHflagshipPATH leads MADE program receiving US$ 11 million to support African companies in developing and scaling diagnostic test production for regional and global markets. Part of US$ 50 million flagship programs to strengthen Africa's regional manufacturing.
- US Pharmacopeia (USP)flagshipUSP leads MedSuRe Africa program receiving US$ 35.5 million to boost production of essential medicines including HIV, malaria, and postpartum hemorrhage treatments along with related quality testing infrastructure.
- Medicines Patent PoolsupportingMedicines Patent Pool receives US$ 1.5 million for complementary work supporting the MedSuRe Africa flagship program for regional manufacturing.
- JhpiegocoreUnitaid and Jhpiego launch US$26.5 million initiative to curb rising antimalarial drug resistance in Africa.
- PoskomcoreUnitaid and CHAI announced new pricing agreement with South Korean company Poskom to dramatically lower cost of AirRay 20 ultraportable digital chest x-ray system, making it available at discounted price to 138 LMICs.
- Japan / NikkisosupportingUnitaid and Japan's Nikkiso partner with Kenya and Tanzania to build liquid medical oxygen facilities in East Africa through project with Japanese government committing funds.
- World Health Organization (WHO)coreUnitaid is a hosted partnership of WHO. Credibility and insight through WHO hosting. Operations administered in accordance with Unitaid's constitution and WHO rules. WHO uses evidence from Unitaid investments to create policy and guidance.
- The Global FundcoreCollaboration with Global Fund to take products and best practices to scale. Global Fund is a major scale-up partner for Unitaid-supported interventions.
Scale indicators17 records
Recent moves7 records
Expansion highlights7 records
Unitaid competitors and assessment
Company assessmentDirect peers
- Gavi, the Vaccine Alliance: Multilateral public-private partnership accelerating vaccine access in LMICs through innovative financing, market shaping, and Gavi-Advanced Market Commitments. Same financing/partnership DNA as Unitaid but focused on immunization.
- Medicines for Malaria Venture (MMV): Public-private partnership developing and delivering malaria treatments. Shares Unitaid's grant-funded, market-shaping approach and operates within the same global health ecosystem with overlapping donor and partner networks.
- PATH: Leads Unitaid's $11M MADE program for African diagnostic manufacturing and is a longstanding implementing partner across Unitaid's investment portfolio. Overlapping mission of accelerating health innovation in LMICs.
- Drugs for Neglected Diseases initiative (DNDi): Not-for-profit R&D organization developing treatments for neglected diseases (sleeping sickness, leishmaniasis, Chagas disease, etc.) with funding from public and philanthropic donors. Closely mirrors Unitaid's grant-funded, partnership-driven model for access-oriented health R&D.
- Clinton Health Access Initiative (CHAI): Operates as Unitaid's direct implementation co-pilot on market-shaping deals (lenacapavir generic pricing for 120 LMICs, AirRay 20 X-ray pricing for 138 LMICs). Both organizations negotiate volume guarantees and pooled procurement across the same disease portfolio.
- FIND (Foundation for Innovative New Diagnostics): Strategic implementation partner for Unitaid's TB diagnostics portfolio ($44M joint investment since 2022) and pooled testing trials. Both organizations focus on introducing diagnostic innovations to LMIC public health systems.
- The Global Fund to Fight AIDS, Tuberculosis and Malaria: Multilateral financing mechanism for the same three diseases Unitaid targets (HIV, TB, malaria), serving as Unitaid's primary scale-up partner to take innovative health products to LMICs. Operates with similar donor-funded, partnership-based model.
- Medicines Patent Pool: Founded by Unitaid in 2010 and still receiving direct Unitaid funding ($1.5M for MedSuRe Africa). MPP negotiates voluntary licenses for HIV, TB, and hepatitis C medicines in LMICs — a core enabler of Unitaid's generic pricing strategy.
- TB Alliance: Non-profit product development partnership advancing faster, cheaper TB regimens, working closely with Unitaid as a co-funder and implementer of TB innovations in LMICs.
Others
- Wellcome Trust: Major philanthropic funder of global health R&D and a current Unitaid donor. While not a direct competitor, Wellcome shapes the same funding and policy ecosystem and increasingly co-invests on issues like pandemic preparedness and climate-health.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Unitaid social profiles
Digital presenceUnitaid financial estimates
Financial estimateRevenue estimate
Valuation estimate
Unitaid leadership team
Management profileNumber of profiles
Profiles7 records
Unitaid funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Unitaid M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Unitaid
What does Unitaid do?
Unitaid finances and accelerates the development, introduction, and scale-up of innovative health products for HIV, tuberculosis, malaria, women's and children's health, and pandemic preparedness in low- and middle-income countries. It does this primarily through grants to implementing partners and market-shaping agreements (volume guarantees, ceiling prices, and technology partnerships) that drive down product costs and accelerate access for the people who need them most.
Is Unitaid a public or private company?
Unitaid is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Unitaid founded?
Unitaid was founded in 2006. It employs 101 to 250 people.
Where is Unitaid based?
Unitaid is headquartered in Geneva, Switzerland, in the Europe region.
How does Unitaid make money?
Two revenue lines are on record. Grants and Donations are the primary driver. The others are innovative Financing.
Who are Unitaid's main competitors?
Direct peers on record are Gavi, the Vaccine Alliance, Medicines for Malaria Venture (MMV), PATH, Drugs for Neglected Diseases initiative (DNDi), Clinton Health Access Initiative (CHAI), FIND (Foundation for Innovative New Diagnostics), The Global Fund to Fight AIDS, Tuberculosis and Malaria, Medicines Patent Pool and TB Alliance. Wellcome Trust is listed as an others.
Does Unitaid have an API?
No public API is recorded for Unitaid.
What industry is Unitaid in?
Unitaid's product category is Global Health Financing and Market Shaping. Its primary akta.pro industry code is HLAJAKAC, Global Health Financing Mechanisms, with a secondary code of HLAJAKAA, Multilateral Global Health Agencies (UN/IFIs). Its NAICS code is 813212 and its SIC code is 8300.